Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Inclusion Criteria: * International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3 to IVA will be included prospectively. * Previous standard treatment based on concomitant chemoradiotherapy regimen. * Karnofsky performance status score ≥70, with estimated life expectancy ≥12 weeks, * Immunocompetent, * Positive research for types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA in plasma at the end of chemoradiotherapy, * Proper hematological, liver and kidney functions. Inclusion criteria will include absolute neutrophils count ≥1.5 x 109/L, platelets ≥100 x 10/L, serum bilirubin ≤ 2.0 x upper limit of normal (ULN), calculated creatinine clearance ≥50 mL/min and alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN. * Patients of child-bearing potential were obligated to use an approved contraceptive method during and for 3 months after the study; * Agree with research procedures, by signing the Informed Consent Form (ICF). Exclusion Criteria: * Previous cervical cancer or other malignancies, * Pregnant women, * Inability to perform concurrent cisplatin based-chemoradiotherapy. * Tumors containing different HPV genotypes * Absence of anatomopathological examination to prove the diagnosis and/or staging examinations.